SERES THERAPEUTICS, INC. (NASDAQ:MCRB) Files An 8-K Regulation FD Disclosure

Item7.01.

On June12, 2017, Seres Therapeutics, Inc. (the Company, we, and
our) posted an updated corporate slide presentation, including
reaffirmed financial guidance and information regarding the
Companys clinical trials, on its website at
www.serestherapeutics.com. Updated clinical trial
disclosures include (i)the initiation of the SER-109 ECORSPOR III
study; (ii)the designation of the SER-109 ECOSPOR III study as a
Phase 3 trial; and (iii)the planned expansion of the SER-262
Phase 1b study and the resulting modification in the timing of
expected study results to early 2018. A copy of the slide
presentation is attached as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated herein by reference.

The information in Item7.01 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is intended to be
furnished and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
filing. The Company undertakes no obligation to update,
supplement or amend the materials attached hereto as Exhibit
99.1.

(d) Exhibits.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements contained in this
report that do not relate to matters of historical fact should be
considered forward-looking statements, including the planned
expansion for the SER-262 Phase 1b study and the timing of study
results for the SER-262 Phase 1b study.

These forward-looking statements are based on managements current
expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied
by the forward-looking statements, including, but not limited to,
the following: we have incurred significant losses, are not
currently profitable and may never become profitable; our need
for additional funding, which may not be available; our limited
operating history; the unpredictable nature of our early stage
development efforts for marketable drugs; the unproven approach
to therapeutic intervention of our microbiome therapeutics; the
lengthy and expensive process of clinical drug development, which
has an uncertain outcome; potential delays in enrollment of
patients which could affect the receipt of necessary regulatory
approvals; potential delays in regulatory approval, which would
impact the ability to commercialize our product candidates and
affect our ability to generate revenue; any fast track or
Breakthrough Therapy designation may not lead to faster
development, regulatory approval or marketing approval; our
possible inability to receive orphan drug designation should we
choose to seek it; our reliance on third parties to conduct our
clinical trials and the potential for those third parties to not
perform satisfactorily; our reliance on third parties to
manufacture our product candidates, which may delay, prevent or
impair our development and commercialization efforts; our lack of
experience in manufacturing our product candidates; the potential
failure of our product candidates to be accepted on the market by
the medical community; our lack of experience selling, marketing
and distributing products and our lack of internal capability to
do so; failure to compete successfully against other drug
companies; potential competition from biosimilars; failure to
obtain marketing approval internationally; post-marketing
restrictions or withdrawal from the market; anti-kickback, fraud,
abuse, and other healthcare laws and regulations exposing us to
potential criminal sanctions; recently enacted or future
legislation; compliance with environmental, health, and safety
laws and regulations; protection of our proprietary technology;
protection of the confidentiality of our trade secrets; changes
in United States patent law; potential lawsuits for infringement
of third-party intellectual property; our patents being found
invalid or unenforceable; compliance with patent regulations;
claims challenging the inventorship or ownership of our patents
and other intellectual property; claims asserting that we or our
employees misappropriated a third-partys intellectual property or
otherwise claiming ownership of what we regard as our
intellectual property; adequate protection of our trademarks;
ability to attract and retain key executives; managing our growth
could result in difficulties; risks associated with international
operations; potential system failures; the price of our common
stock may fluctuate substantially; our executive officers,
directors, and principal stockholders have the ability to control
all matters submitted to the stockholders; a significant portion
of our total outstanding shares are eligible to be sold into the
market; unfavorable or lacking analyst research or reports; and
we are currently subject to securities class action litigation.
These and other important factors discussed under the caption
Risk Factors in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission, or SEC, on May7, 2017 and our
other reports filed with the SEC, could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this report. Any such forward-looking
statements represent managements estimates as of the date of this
report. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to
change. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date of this report.

About SERES THERAPEUTICS, INC. (NASDAQ:MCRB)

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.